The anti-SSA antibodies studied were in the majority of cases anti-Ro52, whereas according to the ACR/EULAR 2016 criteria, it is anti-Ro60 that should be taken into account for the diagnosis of SS. This evidence concerns the gene RO60 and synovial sarcoma.